Purpose: An earlier phase II trial of paclitaxel in patients with metastatic nasopharyngeal carcinoma (NPC) demonstrated a response rate of 22%. Hence we proceeded to study the combination of paclitaxel and carboplatin in these patients.
Introduction
Nasopharyngeal carcinoma (NPC) is common among the Chinese population in Singapore with an age-standardized rate (ASR) of 18.4 per 100000 in males and 7.3 per 100000 in females [1] . In a review by Fong et al. 5% of the patients diagnosed with NPC were found to have systemic disease at presentation [2] , In addition, 30%-60% of those who had locally advanced disease developed distant metastases within five years of diagnosis. Hence, systemic disease is a common problem among patients with NPC.
The high chemoresponsiveness of NPC is well established, and a platinum-based regimen is generally used for palliation in those with metastatic disease [3] . Our experience with the combination of cisplatin and 5-fluorouracil had also demonstrated a response rate of 66%, with a median duration of response of 8 months and a median survival of 11 months [4] . Another study from Singapore reported similar results [5] .
Paclitaxel has shown encouraging activity in squamous cell head and neck cancers [6, 7] . We conducted a phase II study of paclitaxel in metastatic NPC in 1994 using a dose of 175 mg/m 2 infused over three hours every 21 days [8] . A response rate of 22% was obtained with a median duration of response of seven months. We therefore proceeded to study the combination of paclitaxel and carboplatin in patients with metastatic NPC.
Patients and methods

Eligibility criteria
Patients had histologically confirmed undifferentiated carcinoma of the nasopharynx, no prior chemotherapy, radiologically measurable systemic or primary (with no prior radiotherapy) disease, PS ECOG 0-2, normal serum bilirubin, adequate renal, bone marrow, and cardiac function. Written informed consent was required.
Treatment schedule
The combination of paclitaxel and carboplatin was administered every 21 days as follows: i.v. paclitaxel at 175 mg/m 2 infused over three hours with oral dexamethasone 20 mg 12 hours and 6 hours, and i.v. diphenhydramine 25 mg, i.v. cimetidine 300 mg (or i.v. ranitidine 150 mg) 30 minutes prior to paclitaxel as premedications, followed by i.v. carboplatin infused over one hour. Carboplatin was dosed to a target area under the concentration-time-curve (AUC) of 6 using the Calvert formula:
Carboplatindose (mg) = AUC Urget x (Clcr + 25)
Where creatinine clearance (Clcr) was calculated using the CockroftGault formula as follows: Clcr = (0.85 for female)(140-age)(wt in kg)/ 0.81 x serum creatinine in umol/1.
Follow-up
CT scan of the relevant region(s) was obtained for all patients as a baseline and repeated after every two cycles to assess response. Chemotherapy was stopped upon confirmation of stable or progressive disease.
No dose attenuation was allowed. The subsequent cycle of chemotherapy would be delayed by a week if the neutrophil count was less than 1.0 x 10 9 /l. The patient was taken off protocol if haematological recovery took more than two weeks.
Response to treatment was graded using standard criteria. Toxicity was graded according to the World Health Organization toxicity criteria.
Results
Number Percentage   Partial  Complete  Overall  Stable  Progression  Not evaluable   23  1  24  3  2  3   72  3  75  9  6  9 males and the vast majority of the patients were Chinese (97%). Twenty patients (62%) had metastatic disease in two or more sites, and the three common sites of metastatic involvement include the lungs (56%), liver (56%) and bones (47%). Eight patients presented with distant metastases at diagnosis; the rest were diagnosed with recurrent systemic disease with a median disease-free interval of 18 months (range 7-168 months) after radiotherapy. (Table 2) In this study a total of 152 cycles of paclitaxel and carboplatin were administered, eight cycles of which were not evaluable for hematological toxicity. Grade 3-4 granulocytopenia was the most significant hematological toxicity, occurring in 31% of the cycles administered. While only nine patients developed neutropenic sepsis, one of them died of uncontrolled sepsis. Ten patients reported drug fever. Arthralgia/myalgia and peripheral neuropathy (sensory) occurred in 66% and 78% of the patients, respectively, but the majority was of grade 1-2 severity.
Toxicities of treatment
Response (Table 3 ) and survival outcome
The response of distant metastases to the combination of paclitaxel and carboplatin is high, with 24 patients (75%) attaining major responses. Fifteen patients had locoregional disease at entry to the study, of which eight patients, who presented with distant metastases, had had no prior radiotherapy. Five (62%) of the eight patients who did not have prior radiotherapy to the primary site achieved partial responses to chemotherapy in the primary site. However, only one (14%) of the seven patients who had previously had a radical course of radiotherapy to the primary site achieved a partial response of the locoregional disease to chemotherapy. The median time to progression of disease for all patients was seven months (Figure 1) . The median overall survival achieved was 12 months and the one-year survival rate was 52% (Figure 1 ). (Table 1) Between November 1996 and December 1997, 32 patients were accrued to this study. There was a preponderance of
Patient characteristics
Discussion
The results of this study showed that the combination of paclitaxel and carboplatin has activity comparable to that of other platinum-containing regimens, such as cisplatin and 5-fluorouracil. There are obvious advantages to using paclitaxel and carboplatin, namely, the convenience of administration on an outpatient basis requiring less than half a day and the good tolerability of this regimen experienced by most patients. While arthralgia/ myalgia and paraesthesia of the extremities (in particular the upper limbs) were common, these are usually mild to moderate in intensity and generally do not prove bothersome to the patients. The recent data from the North American Intergroup randomized study indicated survival benefit from the use of combined chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma [9] . The combined chemoradiotherapy arm uses cisplatin for three cycles during the radiotherapy phase as a radiosensitizer followed by three further cycles of cisplatin and 5-fluorouracil as adjuvant treatment. The rationale for such a treatment schedule is its potential for improving both locoregional and systemic control, both of which are important in locally advanced nasopharyngeal carcinoma. However, the main disadvantage of such a schedule is the protracted time required to complete the treatment and hence the potential for a problem with patient compliance.
Paclitaxel and carboplatin, both of which are radiosensitizers, when used concurrently with radiation comprise an attractive regimen to consider in this group of patients with locally advanced disease. The use of combined paclitaxel and carboplatin concurrently with radiation in locally advanced NPC could potentially attain the dual goal of improving locoregional and systemic control, without having a more prolonged treatment schedule. A pilot study looking into this is being planned.
